| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
The Israeli pharmaceutical market grew strongly in the 1990s, averaging around
10% per annum. This report is ideal for executives wanting to understand the
key drivers in the pharmaceutical market and have access to a wealth of
statistical data, including five-year market projections. Included with the
report are 3 free quarterly updated outlook reports, enabling you to keep up
to date with market developments for a year.
Includes 3 quarterly updated outlook reports!
Israel's healthcare sector remains amid a period of uncertainty. The
continuing political instability has been a significant factor in this
malaise; healthcare policy has changed frequently and often faced widespread
opposition. Progress within the sector is unlikely in the short term while
government efforts are concentrated around the current dark state of
Israeli-Palestinian affairs.
The Israeli pharmaceutical market grew strongly in the 1990s, averaging around
10% per annum. Whether this level of growth continues, however, remains to be
seen. Recent industry activity has been dominated by new legislation regarding
drug pricing and parallel imports. After years of debate and delay new pricing
regulations were implemented in June 2001, while legislation permitting the
parallel trade of drugs was introduced in September 2000. Both reforms
successfully overcame strong multinational opposition in the Supreme Court.
This move marks a significant change in the relationship between
multinationals and the regulatory authorities; traditionally the latter acted
with the consent of the former with regard to major issues. In 2007, per
capita expenditure on drugs in Israel was estimated at US$423, the highest
level in the Middle East.
Fluctuations in healthcare budgets, where heavy cutbacks were reversed by the
government in the face of widespread opposition by many industry professionals
in 2003, have caused additional concern over the future of national healthcare
after 2002 saw the first ever decrease of healthcare spending in local
currency terms since 1998. Allocations for the health basket are seemingly in
a constant state of uncertainty. On a more positive note, the pharmaceutical
giant Teva continues to record impressive financial growth and has emerged as
a key player in the Israeli economy. In addition, the country continues to
enhance its burgeoning reputation in the field of biotechnology, and possesses
first class research and development facilities.
TABLE OF CONTENTS
ISRAEL: BACKGROUND DATA
- GEOGRAPHY
- POLITICAL OVERVIEW
- ECONOMIC OVERVIEW
- POPULATION
- End-of-Year Population, 1990-2005
- Population by Age & Gender, 2004 (000s)
- DEMOGRAPHIC INDICATORS
- Demographic Indicators, 2003-2005
- Life Expectancy by Gender, 1990-2005 (years)
- Infant Mortality by Cause, 2003
- MORTALITY
- Mortality by Age & Gender, 2003
- Mortality by Cause, per 100,000 Population, 2003
- MORBIDITY
- Selected Infectious Disease, 2002-2005 (per 100,000 population)
- Newly Reported Cases of Male Malignant Neoplasms by Site, 2004
- Newly Reported Cases of Female Malignant Neoplasms by Site, 2004
- New Cases of HIV & AIDS, by Gender, 2000-2005
- Immunisation
- Immunisation Rates for Two-Year-Olds, 1991-2003 (%)
CHARTS
- Population by Age, 2004 (%)
- Causes of Death, 2003 (%)
ISRAEL: HEALTHCARE SYSTEM
- ORGANISATION & ADMINISTRATION
- HEALTH EXPENDITURE
- Health Expenditure by Type, 2001-2003 (NIS millions)
- Health Expenditure by Type, 2001-2003 (US$ millions)
- HOSPITAL SERVICES
- Hospitals by Type, 1990-2005
- Hospitals by Ownership, 1990-2005
- Hospital Beds by Ownership & Department, 2005
- Hospital Beds by Specialty, 2002-2005 (per 100,000 population)
- Hospital Activity
- Average Length of Stay by Specialty, 2002-2005 (days)
- Patient Days by Specialty, 2002-2005 (rate per 1,000 population)
- Discharges by Specialty, 2002-2005 (rate per 1,000 population)
- Bed Occupancy, 2002-2005 (%)
- AMBULATORY CARE
- Day Stations in Hospitals, 1997-2005
- Day Beds by Sector, 1997-2005
- Day Treatments by Sector, 1997-2005
- Dental Services
- Public Health Laboratories
- MEDICAL PERSONNEL
- Employed Persons in Health Services, 1995-2004 (000s)
- Medical Personnel, 1998-2004
CHARTS
- Health Expenditure by Operating Sector, 2003 (%)
ISRAEL: ACCESSING THE PHARMACEUTICAL MARKET
- INTRODUCTION
- REGULATORY ENVIRONMENT
- Pharmaceutical Registration
- Labelling & Packaging
- Good Laboratory Practice (GLP)
- Advertising
- Patent Protection & Intellectual Property Rights
- Pricing and Reimbursement
- 2001 Price Control System
- Reimbursement
- DOMESTIC PRODUCTION
- Trade Associations
- Domestic Producers
- Bio-Dar Ltd.
- Clal Pharmaceutical Resources L.P.
- CTS Ltd.
- Dexxon Ltd.
- Kamada Ltd.
- Karmat Ltd.
- Koffolk Ltd.
- Perrigo Israel Pharmaceuticals Ltd.
- Rafa Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Trima-Israel Pharmaceutical Products Ltd.
- Research & Development
- DIRECTORY
- Government Organisations
- Trade Associations
|
